Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
Physiology based pharmacokinetic (PBPK) modeling and simulation is a useful method for prediction of biodistribution of both macromolecules and small molecules. It can enhance our understanding of the underlying mechanisms of biodistribution and hence may help in rational design of macromolecules used as diagnostic and therapeutic agents. In this review we discuss PBPK modeling and simulation of a radiolabelled Monoclonal Antibody ((111)In-DOTA-hAFP31 IgG) ("MAB") in mice without tumor and in a human with tumor. This study is part of Xemet Co.'s effort to develop a more accurate and reliable PBPK model and simulation platform, which is applicable both for small molecules and macromolecules. The simulated results were fitted to experimental time series data by varying parameters which were not fixed a priori. It was demonstrated that the PBPK model describes the main features of the pharmacokinetics of the studied systems. It was also shown that simulation can be used for evaluating the parameters of the system and scaling up the pharmacokinetics of MAB from mice to man. We identified several areas of improvement and further development needed to improve the accuracy of PBPK simulation for MAB and other macromolecules. It was concluded that the transvascular permeabilities are the most important parameters and more research is needed to enable prediction of permeabilities from molecular characteristics of macromolecules. It would also be necessary to understand better and describe with a more detailed model the microstructure of the tumor and to measure or predict the antigen concentration in tumor. Non-specific, non-saturable binding in other organs/tissues should be understood better and the kinetic constants of the binding should be measured experimentally. Although the metabolism and clearance were neglected in this study they need to be included in more detailed studies. Also the intracellular trafficking of macromolecules, which was not included in this study, shall be included in the more accurate models.
Heiskanen
Tomi
T
Xemet Co. Ltd., Tikasniitynkuja 7, 02200, Espoo. Finland. tomi@xemet.com
Heiskanen
Tomas
T
Kairemo
Kalevi
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000493:pharmacokinetics*; D003198:Computer Simulation; D016503:Drug Delivery Systems; D005260:Female; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007457:Iodine Radioisotopes / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D010539:Permeability; D013045:Species Specificity; D014018:Tissue Distribution; D000509:alpha-Fetoproteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D006573:Heterocyclic Compounds, 1-Ring; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes; D000509:alpha-Fetoproteins; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid